Global Narcolepsy Therapeutics Market Size, Share & Industry Trends Analysis Report By Type, By Product (Sodium Oxybate, Selective Serotonin Reuptake Inhibitor, Central Nervous System Stimulants, Tricyclic Antidepressants), By Regional Outlook and Forecast, 2022 - 2028
Special Offering: Industry Insights | Market Trends | Highest number of Tables | 24/7 Analyst Support
Get in-depth analysis of the COVID-19 impact on the Narcolepsy Therapeutics Market
Market Report Description
The Global Narcolepsy Therapeutics Market size is expected to reach $5 billion by 2028, rising at a market growth of 10.5% CAGR during the forecast period.
Chronic, incapacitating neurologic disease called narcolepsy is characterized by excessive daytime sleepiness (EDS). Modafinil, armodafinil, and stimulants are only a few of the medications used to treat narcolepsy. Others include sodium oxybate and venlafaxine, which are used to treat the symptoms of sleep paralysis and sleep-related hallucinations (e.g. sodium oxybate).
In general, drugs that boost norepinephrine or dopamine release or prevent their reuptake have wake-promoting effects and can help manage EDS, whereas drugs that block serotonin or norepinephrine reuptake have anti-cataplexy benefits. Both EDS and cataplexy are affected by the modification of either histamine H3 receptors (H3Rs) or -aminobutyric acid B (GABAB) receptors.
The most recent approved medications for EDS related to narcolepsy in the European Union and the USA are solriamfetol, a dopamine and norepinephrine reuptake inhibitor, and pitolisant, an H3R antagonist. Many new drugs are being developed and tested as potential treatments for EDS and cataplexy associated with narcolepsy (THN102), including novel Oxybate formulations of low sodium [FT218] and one-nightly [JZP-258], selective norepinephrine reuptake inhibitors (AXS-12), and modafinil and astroglial connexin inhibitors (THN102).
The mechanisms of action, pharmacokinetics, effectiveness, and safety/tolerability of recently authorized and developing therapies for narcolepsy. A chronic, incapacitating neurologic condition of hypersomnolence called narcolepsy is thought to affect 20–67 persons per 100,000 people across the world. Narcolepsy typically begins in the second decade of life; however, a diagnosis is frequently made much later.
Excessive daytime sleepiness (EDS), while not a specific symptom of narcolepsy, is a feature of the illness that must be present in all individuals to make the diagnosis. Up to 60% of patients have cataplexy, an involuntary decrease of muscle tone while awake that is generally brought on by intense emotions. Restless nights, hypnagogic and hypnopompic hallucinations that happen when the user falls asleep and wakes up, and sleep paralysis are other symptoms.
COVID-19 Impact Analysis
During the pandemic, COVID-19 had a detrimental effect on narcolepsy medications. The biggest problem is that patients with narcolepsy can stop taking their medication because they are unable to get their prescriptions filled because of transportation limitations, home quarantines, and hospital cross-infection fears. Additionally, because there is no effective treatment for COVID-19, manufacturers and companies are concentrating more on producing the pharmaceuticals and tools that are required for treating COVID-19.
Market Growth Factors
Growing Healthcare Expenditures
One of the main factors boosting the market's rise is the rising number and size of investments made in the healthcare sector by governments of various countries. It is anticipated that more developing nations would have greater access to high-quality healthcare as a result of their quick economic development and growing healthcare costs. This is viewed as a positive indicator of expansion for the narcolepsy therapeutics industry. The need for various treatment and apparatus has surged in these nations due to the rising insomnia problems.
Increasing Prevalence Of Neurological Conditions
Neurologists treat a wide variety of sleep problems, including narcolepsy, sleep apnea, restless legs syndrome, insomnia, and sleep apnea. Endogenous irregularities are brought on by several illnesses, which interfere with the regular sleep-wake cycle. In the upcoming years, neurological sleep-related diseases are predicted to rise as a significant section of the population ages. The National Institute of Health (NIH) estimates that 20 million Americans occasionally have sleep issues, whereas 40 million Americans suffer from neurological illnesses.
Market Restraining Factors
High Cost Of Narcolepsy Diagnosis & Treatment
One of the main factors holding back the narcolepsy market is the high cost of narcolepsy diagnosis and treatment. Additionally, the term "sleeping problem" refers to a broad range of illnesses with serious negative effects on the health of the individual and huge societal costs. Furthermore, in 2019 the smooth operation of the narcolepsy market is disrupted by the high cost of therapy. Daily functioning is hampered by narcolepsy, which is also connected with a significant financial and medical burden—many patients are fully disabled.
On the basis of Type, the Narcolepsy Therapeutics Market is segmented into Narcolepsy with Cataplexy, Narcolepsy without Cataplexy, and Secondary Narcolepsy. The Narcolepsy with Cataplexy segment acquired the highest revenue share in the narcolepsy therapeutics market in 2021. It is because cataplexy is becoming a more common significant symptom among patients. Throughout the prediction, it is anticipated to hold onto its position.
Based on the Product, the Narcolepsy Therapeutics Market is divided into Central Nervous System Stimulants, Sodium Oxybate, Selective Serotonin Reuptake inhibitors, Tricyclic Antidepressants, and Others. The Central Nervous System Stimulants segment recorded a substantial revenue share in the narcolepsy therapeutics market in 2021. It is because the data analysis of CNS Drugs assesses the time to onset of response to pitolisant for excessive daytime sleepiness (EDS) and cataplexy in adult narcolepsy patients.
|Market size value in 2021||USD 2.5 Billion|
|Market size forecast in 2028||USD 5 Billion|
|Historical Period||2018 to 2020|
|Forecast Period||2022 to 2028|
|Revenue Growth Rate||CAGR of 10.5% from 2022 to 2028|
|Number of Pages||170|
|Number of Tables||278|
|Report coverage||Market Trends, Revenue Estimation and Forecast, Segmentation Analysis, Regional and Country Breakdown, Companies Strategic Developments, Company Profiling|
|Segments covered||Type, Product, Region|
|Country scope||US, Canada, Mexico, Germany, UK, France, Russia, Spain, Italy, China, Japan, India, South Korea, Singapore, Malaysia, Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria|
Region-wise, the Narcolepsy Therapeutics Market is analyzed across North America, Europe, Asia Pacific, and LAMEA. The Asia Pacific region garnered a promising revenue share in the narcolepsy therapeutics market in 2021. It is due to economic growth, a rise in public awareness, high levels of disposable money, a rise in investments in the pharmaceutical and biotechnology industries, and benevolent government efforts. Among the Asia Pacific nations, Japan has been noted as having a high prevalence of narcolepsy.
Free Valuable Insights: Global Narcolepsy Therapeutics Market size to reach USD 5 Billion by 2028
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Jazz Pharmaceuticals plc, Shionogi & Co., Ltd., Teva Pharmaceuticals Industries Ltd., Pfizer, Inc. (Arena Pharmaceuticals, Inc.), Bioprojet, Takeda Pharmaceutical Company Limited, Ligand Pharmaceuticals, Inc., and Graymark Healthcare, Inc.
Scope of the Study
Market Segments Covered in the Report:
- Narcolepsy with Cataplexy
- Narcolepsy Without Cataplexy
- Secondary Narcolepsy
- Sodium Oxybate
- Selective Serotonin Reuptake Inhibitor
- Central Nervous System Stimulants
- Tricyclic Antidepressants
- North America
- Rest of North America
- Rest of Europe
- Asia Pacific
- South Korea
- Rest of Asia Pacific
- Saudi Arabia
- South Africa
- Rest of LAMEA
Key Market Players
List of Companies Profiled in the Report:
- Jazz Pharmaceuticals plc
- Shionogi & Co., Ltd.
- Teva Pharmaceuticals Industries Ltd.
- Pfizer, Inc. (Arena Pharmaceuticals, Inc.)
- Takeda Pharmaceutical Company Limited
- Ligand Pharmaceuticals, Inc.
- Graymark Healthcare, Inc.
Unique Offerings from KBV Research
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free